Selvax Cancer Immunotherapy | Publications
page-template,page-template-full_width,page-template-full_width-php,page,page-id-952,ajax_fade,page_not_loaded,,qode_grid_1300,footer_responsive_adv,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-10.1.2,wpb-js-composer js-comp-ver-5.3,vc_responsive


Selected References

Turning the tumor microenvironment into a self vaccine site.
Nelson D. 2012.
OncoImmunology. 1:6, 989-991.


The “Trojan Horse” approach to tumor immunotherapy: targeting the tumor microenvironment.
Nelson D, Fisher S, Robinson B. 2014.
Journal of Immunology Research. 2014: 789069.


IL-2/CD40-activated macrophages rescue age and tumor-induced T cell dysfunction in elderly mice.
Jackaman C, Dye D, Nelson D. 2014.
AGE. doi:10.1007/s11357-014-9655-y.


Intratumoral interleukin-2/agonist CD40 antibody drives CD4+ -independent resolution of treated-tumors and CD4+ -dependent systemic and memory responses.
Jackaman C, Nelson DJ. 2012.
Cancer Immunology, Immunotherapy. 61(4): 549-560.


Deliberately provoking local inflammation drives tumors to become their own protective vaccine site.
Jackaman C, Lew AM, Zhan Y, Allan JE, Koloska B, Graham PT, Robinson BW, Nelson DJ. 2008.
International Immunology. 20(11): 1467-1479.


Human mesothelioma induces defects in dendritic cell numbers and antigen processing function which predict survival.
Cornwall S, Wikstrom M, Musk A, Alvarez J, Nowak A, Nelson D. 2016.
OncoImmunology. 5(2):e1082028.


Modulation of dendritic cell and T cell cross-talk during aging: The potential role of checkpoint inhibitory molecules.
Gardner J, Mamotte C, Jackaman C, Nelson D. 2017.
Ageing Research Reviews. 38:40-51.


Targeting macrophages rescues age-related immune deficiencies in C57BL/6J geriatric mice.
Jackaman C, Radley-Crabb H, Soffe Z, Shavlakadze T, GroundsM, Nelson D. 2013.
Aging Cell. 12(3):345-357.


IL-2/CD40-driven NK cells install and maintain potency in the anti-mesothelioma effector/memory phase.
Jackaman C, Lansley S, Allan J, Robinson B, Nelson D. 2012.
International Immunology. 24(6):357-368.


CD40-activated B cells contribute to mesothelioma tumor regression.
Jackaman C, Cornwall S, Graham P, Nelson D. 2010.
Immunology and Cell Biology. 89:255-267.